Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients.

Abstract : Everolimus (rapamycin derivative, RAD) is a new immunosuppressive drug that prevents allograft rejection. Herein, the pharmacodynamics of everolimus in human renal-allograft recipients is evaluated. Single doses of everolimus (0.75-10mg), combined with a maintenance immunosuppressive therapy based on CyA, decreased lymphocyte proliferation. In addition, the effect of multiple doses of everolimus (0.75-10mg) given daily for 21 days, to stable renal-allograft patients (n=11), was investigated. Everolimus treatment resulted in immediate inhibition (25-55%) of lymphocyte proliferation in renal-allograft recipients; values returning to baseline by 14 days after cessation of everolimus treatment. Placebo-treated patients showed no decrease in lymphocyte proliferation. Interestingly, everolimus reduced IL-10 synthesis by 20-60% in renal-allograft recipients. Phagocytosis rates were not changed by everolimus. In vitro, everolimus inhibited lymphocyte proliferation and IL-10 synthesis dose dependently in anti-CD3 mAb and LPS stimulated peripheral blood mononuclear cell cultures derived from human volunteers.
Type de document :
Article dans une revue
Cytokine / Cytokines, 2008, 42 (3), pp.306-11. 〈10.1016/j.cyto.2008.02.015〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00408849
Contributeur : Marie Francoise Simon <>
Soumis le : lundi 3 août 2009 - 16:57:48
Dernière modification le : jeudi 20 août 2009 - 14:30:44

Identifiants

Collections

Citation

Torsten Böhler, Johannes Waiser, Steffi Lichter, Brit Schumann, Hans-H Neumayer, et al.. Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients.. Cytokine / Cytokines, 2008, 42 (3), pp.306-11. 〈10.1016/j.cyto.2008.02.015〉. 〈inserm-00408849〉

Partager

Métriques

Consultations de la notice

125